Genomic and non-genomic effects of glucocorticoids: Implications for breast cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 1, 2015, Pages 1-10

  Mitre Aguilar, Irma B ^a,b   Cabrera Quintero, Alberto J ^a,b   Zentella Dehesa, Alejandro ^a,b,c  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Breast cancer; Genomic; Glucocorticoid membrane receptor; Glucocorticoids; Non genomic

Indexed keywords

GLUCOCORTICOID;

BREAST TUMOR; FEMALE; HUMAN;

BREAST NEOPLASMS; FEMALE; GLUCOCORTICOIDS; HUMANS;

EID: 84923047527     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Lecoq L, Vincent P, Lavoie-Lamoureux A and Lavoie JP. Genomic and non-genomic effects of dexamethasone on equine peripheral blood neutrophils. Vet Immunol Immunopathol 2009; 128: 126-31.
2. Moutsatsou P and Papavassiliou AG. The glucocorticoid receptor signalling in breast cancer. J Cell Mol Med 2008; 12: 145-63.
3. Simoncini T and Genazzani A. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148: 281-292.
4. Duma D, Jewell CM and Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol 2006; 102: 11-21.
5. De Bosscher K. Selective Glucocorticoid Receptor modulators. J Steroid Biochem Mol Biol 2010; 120: 96-104.
6. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol 2008; 22: 2215-28.
7. Clark AR, Martins JR and Tchen CR. Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 2008; 283: 25765-9.
8. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K and Schütz G. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995; 9: 1608-21.
9. Tronche F, Opherk C, Moriggl R, Kellendonk C, Reimann A, Schwake L, Reichardt HM, Stangl K, Gau D, Hoeflich A, Beug H, Schmid W, Schütz G. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004; 18: 492-7.
10. Boyle MP, Kolber BJ, Vogt SK, Wozniak DF and Muglia LJ. Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness. J Neurosci 2006; 26: 1971-8.
11. Lu NZ and Cidlowski JA. The origin and functions of multiple human glucocorticoid receptor isoforms. Ann N Y Acad Sci 2004; 1024: 102-23.
12. Zhou J and Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005; 70: 407-17.
13. Vilasco M, Communal L, Mourra N, Courtin A, Forgez P and Gompel A. Glucocorticoid receptor and breast cancer. Breast Cancer Res 2011; 130: 1-10.
14. Revollo JR and Cidlowski JA. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann N Y Acad Sci 2009; 1179: 167-78.
15. Arterbery AS, Fergus DJ, Fogarty EA, Mayberry J, Deitcher DL, Lee Kraus W and Bass AH. Evolution of ligand specificity in vertebrate corticosteroid receptors. BMC Evol Biol 2011; 11: 14.
16. De Bosscher K, Haegeman G and Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010; 10: 497-504.
17. Bai Z and Gust R. Breast cancer, estrogen receptor and ligands. Arch Pharm (Weinheim) 2009; 342: 133-49.
18. Ayroldi E and Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009; 23: 3649-58.
19. Pujols L, Mullol J, Torrego A and Picado C. Glucocorticoid receptors in human airways. Allergy 2004; 59: 1042-52.
20. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proc Am Thorac Soc 2004; 1: 255-63.
21. Bottino MC, Cerliani JP, Rojas P, Giulianelli S, Soldati R, Mondillo C, Gorostiaga MA, Pignataro OP, Calvo JC, Gutkind JS, Amornphimoltham P, Molinolo AA, Lüthy IA and Lanari C. Classical membrane progesterone receptors in murine mammary carcinomas: Agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. Breast Cancer Res Treat 2011; 126: 621-636.
22. Rosen J and Miner JN. The search for safer glucocorticoid receptor ligands. Endocr Rev 2005; 26: 452-464.
23. Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L and Doria A. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011; 10: 305-10.
24. Stahn C and Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
25. Stahn C, Löwenberg M, Hommes DW and Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.
26. Buxant F, Engohan-aloghe C and Noe J. Estrogen Receptor, Progesterone Receptor, and Glucocorticoid Receptor Expression in Normal Breast Tissue, Breast In Situ Carcinoma, and Invasive Breast Cancer. Appl Immunohistochem Mol Morphol 2010; 18: 254-257.
27. Adcock IM and Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384.
28. van der Laan S, Lachize SB, Vreugdenhil E, de Kloet ER and Meijer OC. Nuclear receptor coregulators differentially modulate induction and glucocorticoid receptor-mediated repression of the corticotropin-releasing hormone gene. Endocrinology 2008; 149: 725-32.
29. Ring A and Dowsett M. Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 2004; 11: 643-658.
30. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax no D. 2000. pp. 603-613.
31. Schäcke H and Rehwinkel H. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp Dermatol 2006; 15: 565-573.
32. Lu NZ and Cidlowski JA. Glucocorticoid receptor isoforms generate transcription specificity. Trends Cell Biol 2006; 16: 301-7.
33. Moenter SM and Chu Z. Rapid nongenomic effects of oestradiol on gonadotrophin-releasing hormone neurones. J Neuroendocrinol 2012; 24: 117-21.
34. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K and Wehling M. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 965-1016.
35. Koukouritaki SB, Margioris AN, Gravanis A, Hartig R and Stournaras C. Dexamethasone induces rapid actin assembly in human endometrial cells without affecting its synthesis. J Cell Biochem 1997; 65: 492-500.
36. Zhou J, Li M, Sheng CQ, Liu L, Li Z, Wang Y, Zhou JR, Jing ZP, Chen YZ and Jiang CL. A novel strategy for development of glucocorticoids through non-genomic mechanism. Cell Mol Life Sci 2011; 68: 1405-1414.
37. Gametchu B, Chen F, Sackey F, Powell C and Watson CS. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models. In Steroids 1999; 64: 107-119.
38. Bottino MC and Lanari C. Extra nuclear localization of steroid receptors and non genomic activation mechanisms. Medicina (B. Aires) 2010; 70: 173-184.
39. Powell CE, Watson CS and Gametchu B. Immunoaffinity isolation of native membrane glucocorticoid receptor from S-49++ lymphoma cells: biochemical characterization and interaction with Hsp 70 and Hsp 90. Endocrine 1999; 10: 271-280.
40. Giraldi T, Giovannelli P, Di Donato M, Castoria G, Migliaccio A and Auricchio F. Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal 2010; 4: 161-72.
41. Ordóñez-morán P and Muñoz A. Nuclear receptors Genomic and non-genomic effects converge. Cell Cycle 2009; 11: 1675-1680.
42. Long F, Wang Y, Qi HH, Zhou X and Jin XQ. Rapid non-genomic effects of glucocorticoids on oxidative stress in a guinea pig model of asthma. Respirology 2008; 13: 227-232.
43. Alangari AA. Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med 2010; 5: 133-139.
44. Leis H, Page A, Ramírez A, Bravo A, Segrelles C, Paramio J, Barettino D, Jorcano JL and Pérez P. Glucocorticoid Receptor Counteracts Tu-morigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway. Mol Endocrinol 2004; 18: 303-311.
45. Leite-Dellova DC, Oliveira-Souza M, Malnic G and Mello-Aires M. Genomic and nongenomic dose-dependent biphasic effect of aldosterone on Na+/H+ exchanger in proximal S3 segment: role of cytosolic calcium. Am J Physiol Renal Physiol 2008; 295: F1342-F1352.
46. Rose JD and Moore FL. A neurobehavioral model for rapid actions of corticosterone on sensorimotor integration. In Steroids 1999; 64: 92-99.
47. Orchinik M, Murray TF and Moore FL. A corticosteroid receptor in neuronal membranes. Science 1991; 252: 1848-1851.
48. Benten WP, Lieberherr M, Sekeris CE and Wunderlich F. Testosterone induces Ca2+ influx via non-genomic surface receptors in activated T cells. FEBS Lett 1997; 407: 211-214.
49. Han JZ, Lin W and Chen YZ. Inhibition of ATP-induced calcium influx in HT4 cells by glucocorticoids: Involvement of protein A. Acta Pharmacol Sin 2005; 26: 199-204.
50. Falkenstein E, Tillmann HC, Christ M, Feuring M and Wehling M. Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52: 513-556.
51. Löwenberg M, Stahn C, Hommes DW and Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008; 73: 1025-1029.
52. Keith BD. Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 2008; 8: 84.
53. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002; 360: 1969-70.
54. Herr I and Marme A. Glucocorticoids and Progression of Breast Cancer Commentary ND ES SC. December. 2005. pp. 1415-1416.
55. Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P and Gompel A. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res Treat 2013; 142: 283-96.
56. Gruver-Yates AL and Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells 2013; 2: 202-23.
57. Machuca C, Mendoza-Milla C, Córdova E, Mejía S, Covarrubias L, Ventura J and Zentella A. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol 2006; 7: 9.
58. Ouatas T, Halverson D and Steeg PS. Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor. Clin Cancer Res 2003; 9: 3763-72.
59. Toy EP, Lamb T, Azodi M, Roy WJ, Woo HH and Chambers SK. Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells. Breast Cancer Res Treat 2011; 129: 411-9.